Low Sexual Desire in Women: What’s Really Going On and What Actually Helps

Low sexual desire in women is one of the most common — and most undertreated — concerns brought to doctors. If you’re struggling with low sexual desire in women, understanding the causes can open doors to evidence-based treatments and compassionate care in Palm Beach.

By Mark G. Agresti, MD  |  Board-Certified Integrative Psychiatrist  |  Palm Beach, FL

Of all the complaints women quietly carry into a physician’s office — or never mention at all — low sexual desire may be the most stigmatized and least addressed. Women are often told it’s “just stress,” reassured it will pass, or sent away with a pamphlet about relationship communication. Rarely are they offered a systematic biological, psychological, and relational evaluation.

That silence has a cost. Hypoactive Sexual Desire Disorder (HSDD) — characterized by persistently low or absent desire for sexual activity that causes personal distress — affects an estimated 10–15% of adult women. When you expand the lens to subclinical low desire that nonetheless diminishes quality of life, the numbers are considerably higher. And yet, compared to the robust pharmacological pipeline developed for men’s sexual health, the treatment landscape for women remains thin, underutilized, and poorly understood by most clinicians.

This article is intended to change that — for patients, partners, and the clinicians who treat them.

Key point: Low sexual desire in women is multifactorial. Effective treatment requires identifying whether the primary drivers are hormonal, neurobiological, psychological, relational, or — most often — a combination of all four.

Understanding Female Sexual Desire: It’s Not a Simple Drive

Male sexual desire is often modeled as a relatively linear drive: arousal leads to desire leads to action. Female desire is better understood as a responsive system. The pioneering work of Dr. Rosemary Basson and others established that women’s desire frequently emerges in context — in response to intimacy, emotional safety, physical stimulation, and the perceived absence of inhibitors — rather than arising spontaneously from within.

This distinction matters clinically. A woman who reports “never wanting sex anymore” may, when explored carefully, be describing the absence of spontaneous desire but still experience responsive desire under the right conditions. That’s a very different clinical picture than someone with complete sexual anhedonia, and it points toward different interventions.

The dual control model (Bancroft & Janssen) frames sexual response as a balance between excitatory and inhibitory processes. Women with low desire may have insufficient activation of the sexual excitation system (SES), excessive engagement of the sexual inhibition system (SIS), or — typically — both. Treatment, framed this way, involves both amplifying the accelerator and releasing the brakes.

Common Causes of Low Libido in Women

Hormonal Factors

Testosterone is frequently overlooked as a driver of female libido, in part because “testosterone” is culturally coded as a male hormone. In reality, testosterone is the most abundant biologically active sex hormone in women, and free testosterone levels are directly associated with sexual desire, arousal, and satisfaction. Androgen levels decline progressively across the reproductive lifespan — dropping roughly 50% between the 20s and 40s — and fall precipitously with surgical menopause.

Estrogen deficiency, particularly in perimenopause and menopause, contributes to genitourinary syndrome (vaginal dryness, atrophy, dyspareunia), which creates a pain-avoidance loop that further suppresses desire. Even in younger women, hormonal contraceptives — particularly combined oral contraceptives — can suppress free testosterone by increasing sex hormone-binding globulin (SHBG), reducing the bioavailable fraction of an already limited androgen supply.

Thyroid dysfunction (both hypo- and hyperthyroidism) and elevated prolactin levels (from medications or pituitary pathology) are underdiagnosed contributors that should be ruled out in any systematic workup.

Neurobiological and Psychiatric Factors

The central nervous system is the primary organ of female sexual response. Depression is profoundly associated with low desire — and this relationship runs in both directions, as low libido itself frequently contributes to depressed mood, shame, and relational distress.

SSRIs and SNRIs, the most commonly prescribed antidepressants, carry sexual side effects in an estimated 30–70% of users — including reduced desire, delayed orgasm, and anorgasmia. This creates a clinical bind: the treatment for depression frequently worsens sexual function, which in turn can worsen depression. Bupropion, mirtazapine, and vilazodone are notable exceptions with more favorable sexual side effect profiles. (For a deeper discussion of SSRI-related sexual dysfunction, see my earlier article on this topic.)

Anxiety disorders — particularly generalized anxiety and trauma-related presentations — engage the inhibitory systems described above. A hypervigilant nervous system is not a sexually receptive one. Women with unaddressed PTSD or histories of sexual trauma frequently present with low desire as a primary complaint, and this etiology requires trauma-focused psychotherapy as a cornerstone of treatment.

Relationship and Contextual Factors

Relationship quality is among the strongest predictors of sexual desire in women. Emotional disconnection, unresolved conflict, lack of nonsexual affection, and inequitable division of labor all suppress desire — often before any conscious awareness of dissatisfaction. The “invisible load” of caregiving, domestic management, and professional demands creates a chronic drain on the attentional and emotional resources that female desire requires.

Partner factors — including partner sexual dysfunction, changes in attraction, and attachment dynamics — must be assessed. Desire is relational, and treating one partner in isolation frequently yields limited results.

For women seeking individualized evaluation of relationship patterns, concierge psychiatry services can provide a holistic and integrated approach.

Medical and Medication Contributors

• Chronic pain conditions (fibromyalgia, endometriosis, pelvic floor dysfunction)
• Cardiovascular disease and diabetes (vascular contributions to arousal)
• Autoimmune disorders and systemic inflammation
• Sleep disorders, particularly obstructive sleep apnea
• Antihypertensives (beta-blockers, spironolactone)
• Opioids (suppress testosterone and blunt dopaminergic reward)
• Antipsychotics (prolactin elevation and dopamine blockade)
• Benzodiazepines (CNS inhibition and blunted affect)

If you are concerned your medications may be affecting your libido, a comprehensive psychiatric telehealth evaluation can help identify contributors and solutions.

Evidence-Based Treatment Approaches

FDA-Approved Pharmacological Options

Two medications are currently FDA-approved specifically for HSDD in women:

Both medications have modest effect sizes in clinical trials. They work better in women with primarily neurobiological/psychological HSDD and less well when hormonal deficiency or relationship factors are the dominant drivers. Neither should be considered first-line in isolation.

Testosterone Therapy

Despite the absence of an FDA-approved testosterone formulation for women in the United States, testosterone therapy for female sexual dysfunction has a substantial evidence base. A 2019 systematic review and meta-analysis in The Lancet Diabetes & Endocrinology concluded that testosterone was effective for postmenopausal women with low desire, improving desire, arousal, orgasm frequency, and sexual satisfaction, with an acceptable short-term safety profile.

In clinical practice, off-label use of compounded testosterone — typically delivered as a 0.5–2% topical cream or gel applied to the inner thigh or labia majora — is common and generally well-tolerated. Physiological dosing (targeting free testosterone in the upper normal female range, not supraphysiological levels) avoids most virilizing side effects. Monitoring every 3–6 months with free and total testosterone, SHBG, hematocrit, and lipid panel is standard practice.

For women on combined oral contraceptives with SHBG-mediated androgen suppression, switching to a non-oral route (patch, ring, IUD) can meaningfully increase bioavailable testosterone without any exogenous androgen supplementation.

Menopausal Hormone Therapy

For peri- and postmenopausal women, addressing estrogen deficiency is often the first and most impactful intervention. Systemic estrogen therapy (oral, transdermal, or vaginal ring) restores genital blood flow, lubrication, and tissue integrity — removing the pain and avoidance that suppress desire. Local vaginal estrogen (cream, suppository, ring) is effective for genitourinary symptoms with minimal systemic absorption and can be used even in women with a history of hormone-sensitive cancers (in consultation with their oncologist).

Ospemifene (Osphena), an oral SERM with estrogenic activity in vaginal tissue, offers a non-estrogen option for women who cannot or prefer not to use topical estrogen.

Bupropion

Bupropion (a dopamine-norepinephrine reuptake inhibitor) has off-label but reasonably well-supported evidence for improving sexual desire in women — both as a primary treatment for HSDD and as an antidote to SSRI-induced sexual dysfunction. Its mechanism (dopaminergic and noradrenergic activation) aligns with the neurobiological model of desire as a reward-seeking behavior. Starting doses of 150 mg SR or XL are typically well-tolerated; sexual effects often emerge within 2–4 weeks.

Psychotherapy and Couples Interventions

Cognitive-behavioral sex therapy (CBST) addresses the cognitive distortions, negative schemas, and avoidance behaviors that frequently maintain low desire. Mindfulness-based interventions — particularly those developed by Dr. Lori Brotto — have strong evidence for desire and arousal concerns, improving interoceptive awareness and reducing spectatoring (self-focused distraction during sexual activity).

Couples therapy and Emotionally Focused Therapy (EFT) are indicated when relational disconnection is a primary driver. In many cases, improving emotional intimacy, equitable partnership dynamics, and nonsexual affection is more impactful than any pharmacological intervention.

Integrative and Lifestyle Approaches

The following lifestyle factors have meaningful evidence for supporting sexual health in women:

• Regular aerobic exercise — improves body image, testosterone levels, and mood; directly associated with higher sexual desire and satisfaction
• Sleep optimization — a single extra hour of sleep has been associated in research with higher next-day sexual desire in women
• Stress reduction — cortisol is functionally antagonistic to sexual desire; chronic HPA axis activation suppresses gonadal function
• Reducing or eliminating alcohol — while acutely disinhibiting, chronic alcohol use suppresses testosterone and disrupts sleep architecture
• Pelvic floor physical therapy — indicated for dyspareunia, vaginismus, and any pain-avoidance pattern contributing to desire suppression
• Nutritional psychiatry considerations — omega-3 fatty acids, adequate zinc (critical for testosterone synthesis), and vitamin D optimization are foundational supports worth addressing

If you’d like to explore integrative options and lifestyle support, see our services for comprehensive psychiatry in Palm Beach.

A Note on the Role of Psychiatry

Female sexual desire problems sit at the intersection of psychiatry, endocrinology, gynecology, and relational medicine — and fall cleanly within none of them. The result is that many women see multiple specialists, receive treatment for only one dimension of a multidimensional problem, and fail to improve.

Integrative psychiatry is particularly well-positioned to address this gap. The psychiatric evaluation — which considers neurobiological drivers, mood, anxiety, trauma, medications, relationship function, and hormonal context together — is exactly the kind of comprehensive assessment that sexual health concerns require. When a woman comes in describing low libido that started “around the time I went on Lexapro” or “after my second child,” the psychiatrist can hold all of those threads simultaneously.

Treatment is most effective when it is individualized, biologically informed, and relationally aware — addressing the accelerators and the brakes, the hormones and the history, the neurobiology and the narrative.

If you’re a woman in South Florida struggling with low sexual desire — or a clinician looking to better serve this population — I welcome the conversation. My practice specializes in integrative psychiatry for adults, with a particular focus on the hormonal, neurobiological, and relational dimensions of mental and sexual health.

Concierge Integrative Psychiatry · Palm Beach, FL · Statewide Telehealth

Ready to explore a comprehensive, individualized approach to your mental and sexual health?

Schedule an appointment

Frequently Asked Questions

What causes low sexual desire in women?

Low sexual desire in women can be caused by hormonal changes, psychiatric conditions like depression or anxiety, relationship factors, chronic medical issues, and certain medications. A comprehensive evaluation can help pinpoint contributors.

Can medication help with low sexual desire in women?

Yes, medications like Flibanserin (Addyi), Bremelanotide (Vyleesi), and off-label testosterone can be considered. It’s important to work with a psychiatrist familiar with women’s sexual health for personalized options.

Is outpatient detox relevant for hormone or medication-induced libido changes?

If you’re taking medications such as benzodiazepines, opioids, or antidepressants and suspect they affect your libido, outpatient detox can be a step toward improving sexual health under professional supervision.

How can I get help for low sexual desire in Palm Beach, FL?

Contact Dr. Mark Agresti or schedule an appointment for a confidential integrative evaluation and individualized treatment plan. Telehealth options are available for residents throughout Florida.